A Study to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2019
Price : $35 *
At a glance
- Drugs Fenofibrate/pravastatin (Primary) ; Atorvastatin
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- Acronyms PRADA
- Sponsors Yoo Young Pharmaceutical
- 27 Sep 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 30 Aug 2017 Planned number of patients changed from 366 to 302.